PP
ANEB

Praetorian PR’s Anebulo Pharmaceuticals ANEB Stock Holding History

Praetorian PR’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-177,292
Closed -$542K – 14
2023
Q3 		$542K Sell
177,292
-2,713
-2% -$7.52K 0.27% 24
2023
Q2 		$423K Buy
+180,005
New +$449K 0.25% 24

Other funds holding ANEB

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Praetorian PR's ANEB Position: Q4 2023 in Review

Praetorian PR sold out of Anebulo Pharmaceuticals (ANEB) in Q4 2023, closing a stake of 177,292 shares — an estimated $542K sold.

Praetorian PR first reported a position in ANEB in Q2 2023 and held it in 2 quarters. The position peaked at $542K in Q3 2023. 14 funds tracked by Wall St. Rank hold ANEB as of Q4 2023.

  • Praetorian PR reported no remaining Anebulo Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Praetorian PR sold 177,292 Anebulo Pharmaceuticals shares in Q4 2023, an estimated $542K.
  • Praetorian PR first reported a position in Anebulo Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Praetorian PR's Anebulo Pharmaceuticals position peaked at $542K in Q3 2023.
  • 14 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q4 2023.

Based on Praetorian PR's 13F filing for Q4 2023, filed 14 Feb 2024.